CANF Stock Forecast & Price Target

Can-Fite Biopharma Ltd exhibits a compelling upside potential driven by its innovative pipeline targeting the A3 adenosine receptor, particularly with candidates like Namodenoson and Piclidenoson, which are approaching significant clinical milestones. The projections indicate risk-adjusted global sales for Namodenoson reaching approximately $19.7 million by 2031, with a potential escalation of total product revenues from around $3 million in 2027 to $126 million by 2031, reflecting a strong anticipated market presence. Furthermore, positive clinical outcomes, including a patient achieving a complete response with prolonged survival on Namodenoson, bolster confidence in the company's ability to secure marketing approvals in key markets.

Can Fite Biopharma faces significant challenges that negatively impact its financial outlook, including potential hurdles in product commercialization and market penetration, which may lead to reduced revenue projections. The company's financial performance is marked by a net loss of $4.9 million for the first half of 2025 and projected further losses totaling $10 million for the year, contributing to concerns about future dilution and decreasing price targets. Additionally, delays in obtaining regulatory approvals and issues related to intellectual property protection could further hinder Can Fite’s ability to generate revenue and capitalize on its clinical pipeline.